Trial Profile

Open label randomized phase III study of weekly docetaxel and docetaxel every 3 weeks in patients with metastatic breast cancer, resistant to prior chemotherapy.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Mar 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary)
Indications Advanced breast cancer
Focus Therapeutic Use
Acronyms TAX-613

Most Recent Events

12 Oct 2009 New source identified and integrated (Netherlands Trial Register) (NTR1944).
12 Oct 2009 New source identified and integrated (Netherlands Trial Register) (NTR1944).
23 Aug 2009 Planned initiation date changed from 1 Feb 2001 to 18 Jul 2000 as reported by Netherlands Trial Register.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com